ArticleNature nanotechnology2022
Nanomedicine platform for targeting activated neutrophils and neutrophil-platelet complexes using an α
Open access · bronzeAbstract read
In one paragraph
Article in Nature nanotechnology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 45 papers.
0numbers the graph read from it
0cells of the map it votes in
45citing papers in PubMed
6.9field-weighted citation impact, top 2% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
45 citing papers in PubMed, 86 citations in OpenAlex.
- Living Inorganic Nanomaterials: Design, Preparation, and Biomedical Applications.Advanced materials (Deerfield Beach, Fla.) · 2026Review
- Targeting NETosis in the Lung: Respiratory Delivery of Neutrophil-Specific NEBP-Liposomes for Enhanced Therapy of Acute Lung Injury.Molecular pharmaceutics · 2026Article
- Engineered Neutrophils in Translational Medicine: Gene Editing, Nanotechnology, and AI-Driven Clinical Breakthroughs.Advanced healthcare materials · 2026Review
- A neutrophil-tumor cascade-targeting Trojan horse for heterobifunctional prodrug delivery to enhance cGAS-STING cancer immunotherapy.Journal of nanobiotechnology · 2026Article
- CD71BMC nephrology · 2026Article
- CAR-neutrophils produced in vivo to treat glioma.Nature biomedical engineering · 2026Article
- Neutrophil CD14 is a driver and a therapeutic target for deep vein thrombosis.Blood advances · 2026Article
- Harnessing Targeted Polymerized Salicylic Acid Particles to Mitigate Neutrophil-Driven Inflammation.ACS biomaterials science & engineering · 2026Article
- Rod-Shaped Nanotherapeutics Alleviate Rheumatoid Arthritis by Precisely Disrupting Platelet-Mediated Pathological Crosstalk via a Morphology-Dependent Manner.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026Article
- Crossing the Blood-Brain Barrier with Molecularly Imprinted Polymeric Nanocarriers: An Emerging Frontier in Brain Disease Therapy.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026Review
- In Situ Assembly of Transformable Monopeptide on Activated Neutrophils Attenuates NETs-Induced Hepatocellular Carcinoma Metastasis by Disrupting NE Nuclear Translocation.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026Article
- Engineered neutrophil membrane nanosystem for targeted siRNA therapy in myocardial ischemia-reperfusion injury.Journal of nanobiotechnology · 2025Article
- Harnessing biomaterials for tuning inflammation: A neutrophil-centric perspective.Materials today. Bio · 2025Review
- Advanced nanotherapies for precision treatment of inflammatory lung diseases.Bioactive materials · 2025Review
- Advanced Nanoparticle Therapeutics for Targeting Neutrophils in Inflammatory Diseases.Advanced healthcare materials · 2025Review
- Platelet-derived biomimetic nanoplatforms: a promising drug delivery strategy for cardiovascular disease.Journal of nanobiotechnology · 2025Review
- Harnessing smart nanomaterials to reprogram neutrophil plasticity in immune modulation.Journal of nanobiotechnology · 2025Review
- Role of Neutrophils in Homeostasis and Diseases.MedComm · 2025Review
- [Advancement in neutrophil-based drug delivery systems].Zhejiang da xue xue bao. Yi xue ban = Journal of Zhejiang University. Medical sciences · 2025Review
- Article
Corrections and comments
- Commented on by
Authors and funding
26 authors at 9 institutions in 2 countries.
Michelle A Cruz *Department of Pathology, Immunology Training Program, CWRU School of Medicine, Cleveland, OH, USA.
Dillon Bohinc *Department of Medicine, Hematology and Oncology Division, CWRU School of Medicine, Cleveland, OH, USA.
Elizabeth A Andraska *Department of Surgery, Division of Vascular Surgery, University of Pittsburgh Medical Center, Pittsburgh, PA, USA.ORCID http://orcid.org/0000-0001-6536-070X
Jurgis AlvikasDepartment of Surgery, Pittsburgh Trauma Research Center, University of Pittsburgh Medical Center, Pittsburgh, PA, USA.
Shruti RaghunathanDepartment of Biomedical Engineering, Case Western Reserve University (CWRU), Cleveland, OH, USA.
Nicole A MastersDepartment of Civil and Environmental Engineering, Colorado School of Mines, Golden, CO, USA.
Nadine D van KleefCDL Research, University Medical Center Utrecht, Utrecht University, Utrecht, The Netherlands.ORCID http://orcid.org/0000-0001-7162-9277
Kara L BaneDepartment of Medicine, Hematology and Oncology Division, CWRU School of Medicine, Cleveland, OH, USA.
Kathryn HartDepartment of Biomedical Engineering, Case Western Reserve University (CWRU), Cleveland, OH, USA.
Kathryn MedrowDepartment of Biomedical Engineering, Case Western Reserve University (CWRU), Cleveland, OH, USA.
Michael SunDepartment of Biomedical Engineering, Case Western Reserve University (CWRU), Cleveland, OH, USA.
Haitao LiuDepartment of Ophthalmology, Children's Hospital of University of Pittsburgh School of Medicine, Pittsburgh, PA, USA.ORCID http://orcid.org/0000-0002-3757-779X
Shannon HaldemanDepartment of Surgery, Pittsburgh Trauma Research Center, University of Pittsburgh Medical Center, Pittsburgh, PA, USA.
Ankush BanerjeeDepartment of Biomedical Engineering, Case Western Reserve University (CWRU), Cleveland, OH, USA.
Emma M LessieurCenter for Translational Vision Research, Gavin Herbert Eye Institute, University of California Irvine, Irvine, CA, USA.ORCID http://orcid.org/0000-0001-9120-0291
Kara HagemanDepartment of Biomedical Engineering, Case Western Reserve University (CWRU), Cleveland, OH, USA.
Agharnan GandhiDepartment of Medicine, Hematology and Oncology Division, CWRU School of Medicine, Cleveland, OH, USA.ORCID http://orcid.org/0000-0001-9772-6841
Maria de la FuenteDepartment of Pharmacology, CWRU School of Medicine, Cleveland, OH, USA.
Marvin T NiemanDepartment of Pharmacology, CWRU School of Medicine, Cleveland, OH, USA.
Timothy S KernCenter for Translational Vision Research, Gavin Herbert Eye Institute, University of California Irvine, Irvine, CA, USA.
Coen MaasCDL Research, University Medical Center Utrecht, Utrecht University, Utrecht, The Netherlands.
Steven de MaatCDL Research, University Medical Center Utrecht, Utrecht University, Utrecht, The Netherlands.
Keith B NeevesDepartment of Bioengineering and Pediatrics, Section of Hematology, Oncology, and Bone Marrow Transplant Hemophilia and Thrombosis Center, University of Colorado Denver, Anschutz Medical Campus, Aurora, CO, USA.
Matthew D NealDepartment of Surgery, Pittsburgh Trauma Research Center, University of Pittsburgh Medical Center, Pittsburgh, PA, USA.ORCID http://orcid.org/0000-0001-8931-6236
Anirban Sen GuptaDepartment of Pathology, Immunology Training Program, CWRU School of Medicine, Cleveland, OH, USA. axs262@case.edu.ORCID http://orcid.org/0000-0002-5773-0667
Evi X StavrouDepartment of Medicine, Hematology and Oncology Division, CWRU School of Medicine, Cleveland, OH, USA. evi.stavrou@case.edu.ORCID http://orcid.org/0000-0002-6075-7609
Case Western Reserve University · USUniversity of Pittsburgh Medical Center · USUtrecht University · NLColorado School of Mines · USUnited States Department of Veterans Affairs · USUniversity Hospitals Cleveland Medical Center · USUniversity of California, Irvine · USUniversity of Colorado Anschutz Medical Campus · USUniversity of Pittsburgh · US
Funding
Clinical and Translational Science Collaborative of ClevelandUL1TR002548 · NCATS · CASE WESTERN RESERVE UNIVERSITY · PI MCCOMSEY, GRACE A · 2018 to 2022
$35.5MMEDICAL SCIENTIST TRAINING PROGRAMT32GM007250 · NIGMS · CASE WESTERN RESERVE UNIVERSITY · PI HUANG, ALEX YEE-CHEN · 1985 to 2023
$33.4MNovel therapies to inhibit Diabetic RetinopathyR24EY024864 · NEI · UNIVERSITY OF CALIFORNIA-IRVINE · PI KERN, TIMOTHY S · 2015 to 2019
$8.1MVascular Surgery Research Training (VascTrain) ProgramT32HL098036 · NHLBI · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI Edith Tzeng · 2010 to 2026
$7.2MMedical Scientist Training Program at Case Western Reserve UniversityT32GM152319 · NIGMS · CASE WESTERN RESERVE UNIVERSITY · PI Heather Broihier, Alex Yee-Chen Huang · 2024 to 2026
$5.1MThe role of protease activated receptors on platelets.R01HL098217 · NHLBI · CASE WESTERN RESERVE UNIVERSITY · PI NIEMAN, MARVIN THOMAS · 2010 to 2024
$4.6MHeteromutivalent Peptide-Lipid Nanoconstructs as Artificial Platelet AnaloguesR01HL121212 · NHLBI · CASE WESTERN RESERVE UNIVERSITY · PI SEN GUPTA, ANIRBAN · 2014 to 2024
$4.1MInflammation in Vascular Injury and RepairR37HL057506 · NHLBI · CASE WESTERN RESERVE UNIVERSITY · PI SIMON, DANIEL I · 2007 to 2016
$4.1MMechanistic Elucidation and Targeted Therapy of Platelet Dysfunction After TraumaR35GM119526 · NIGMS · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI NEAL, MATTHEW D · 2016 to 2025
$3.9MRole of Photoreceptors in the Pathogenesis of Diabetic RetinopathyR01EY022938 · NEI · UNIVERSITY OF CALIFORNIA-IRVINE · PI KERN, TIMOTHY S · 2013 to 2021
$3.7MMechanisms of platelet exosome-mediated acute chest syndrome in sickle cell diseaseR01HL141080 · NHLBI · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI NEAL, MATTHEW D, NOVELLI, ENRICO M · 2019 to 2022
$3.1MNRSA Training CoreTL1TR002549 · NCATS · CASE WESTERN RESERVE UNIVERSITY · PI HARDING, CLIFFORD V · 2018 to 2022
$2.9MBLRD VA I01 BX003851BLRD VA IK6 BX003604NCATS NIH HHS TL1 TR002549NCATS NIH HHS UL1 TR002548NEI NIH HHS R01 EY022938NEI NIH HHS R01 EY033002NEI NIH HHS R24 EY024864NHLBI NIH HHS F32 HL090304NHLBI NIH HHS F32 HL149207NHLBI NIH HHS R01 HL098217NHLBI NIH HHS R01 HL120728NHLBI NIH HHS R01 HL121212NHLBI NIH HHS R01 HL129179NHLBI NIH HHS R01 HL137695NHLBI NIH HHS R01 HL141080NHLBI NIH HHS R01 HL151984NHLBI NIH HHS R33 HL141794NHLBI NIH HHS R37 HL057506NHLBI NIH HHS T32 HL098036NHLBI NIH HHS T32 HL105338NIGMS NIH HHS R35 GM119526NIGMS NIH HHS T32 GM007250NIGMS NIH HHS T32 GM152319
Abstract
Targeted drug delivery to disease-associated activated neutrophils can provide novel therapeutic opportunities while avoiding systemic effects on immune functions. We created a nanomedicine platform that uniquely utilizes an α
Indexed as
alpha 1-Antitrypsin DeficiencyLeukocyte ElastaseAnimalsHumansHydroxychloroquineMiceNanomedicineNeutrophilsHydroxychloroquineLeukocyte Elastase
Identifiers
What OpenQuestion holds
Textmetadata
LicenceTDM
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.